⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582725 | 0.62 | — | — | |
| SCHEMBL3699545 | 0.57 | — | — | |
| SCHEMBL2303039 | 0.57 | — | — | |
| SCHEMBL19028235 | 0.54 | — | — | |
| SCHEMBL19275003 | 0.53 | — | — | |
| SCHEMBL6163559 | 0.53 | ESR2 (0.32) | — | |
| SCHEMBL3668297 | 0.49 | — | — | |
| Bromide SCHEMBL21804716 | 0.35 | — | — | |
| SCHEMBL13719072 | 0.34 | — | — | |
| Phosphine SCHEMBL7197129 | 0.29 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250353820-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338220-B2 | Antiviral pyrazolopiridinone compounds | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-115335378-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-1646632-A2 | SUBSTITUTED TETRAHYDRO-1 I H /I -PYRAZOLO 3,4-C|PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1567517-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Pharmaceuticals Corporation (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
| WO-2005007653-A3 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005007653-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007653-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | WO | disclosed |
| US-20040157904-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004050650-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050651-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |